Navigation Links
Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
Date:6/17/2009

Product shipment has begun

PITTSBURGH, June 17 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This strength is in addition to Mylan's currently marketed 15 mg and 30 mg strengths of the product.

Temazepam Capsules are the generic version of Mallinckrodt's Restoril(R), a sleep aid, which had total U.S. sales of approximately $6 million for the 12 months ending March 31, according to IMS Health. Mylan has begun shipping this product.

Currently, Mylan has 118 ANDAs pending FDA approval representing $82.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, which represent $16.7 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
2. Mylan Announces Successful Matrix Delisting Offer
3. Mylan Announces Change in Board Leadership
4. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
5. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
8. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
9. Mylan Announces Clarinex(R) Settlement Agreement
10. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
11. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , ... March 01, 2017 , ... ... healing grace in the lives of those who hear His voice. “Cleansing Thoughts; ... a retired Christian bookstore proprietor who enjoys boating, gardening and crocheting baby items ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... “Our Pure Need of Obedience to the ... preparation for His return. “Our Pure Need of Obedience to the Law of God” is ... to attend missionary school. He and his wife, Anika, and children have since dedicated their ...
(Date:2/28/2017)... ... ... e-Zest Solutions ( http://www.e-zest.com ) – Digital Transformation leader ... intelligent mobile platform that is enabling sales people at small businesses to Fortune ... users in mind unlike most enterprise software, to improve their productivity by making ...
(Date:2/28/2017)... ... February 28, 2017 , ... Many of the country’s top ... Solutions to Healthcare’s Greatest Challenges,” during Intalere’s 2017 Executive Forum, taking place March ... Forum assembles the best and brightest healthcare leaders to exchange experiences, expertise and ...
(Date:2/28/2017)... Baltimore, MD (PRWEB) , ... February 28, 2017 , ... ... Healthcare are co-hosting a Wellness Day on March 4, 2017 from 10:00 a.m. to ... San Mateo and Menaul Blvds. , The goal of the Wellness Day is to ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... , March 1, 2017 The global  Intraoperative Neuromonitoring ... a new report by Grand View Research, Inc. The intraoperative neuromonitoring market is ... to the hospitals adopting intraoperative monitoring in a wide spectrum of surgeries. ... ... Grand View Research Logo ...
(Date:2/28/2017)... -- Prefilled Syringes Market: Scope and Segmentation Download ... report provides a forecast and analysis of the ... levels. It provides historical data of 2015 along ... of revenue (US$ Mn) and volume (Bn Units). ... an outlook on prefilled syringes consumption globally. It ...
(Date:2/28/2017)... , Feb. 28, 2017 Persistence Market ... global dysphagia management market in a new publication ... Forecast 2016-2024." As the name suggests, we have ... geographical regions and on the basis of the ... assessment of the opportunities available to all the ...
Breaking Medicine Technology: